Home > > > > > Report Detail

Malignant Mesothelioma - Pipeline Review, H2 2019

Publisher Name :
Date: 25-Nov-2019
No. of pages: 976
Inquire Before Buying

Malignant Mesothelioma - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2019, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 43, 33, 25, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 6 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Malignant Mesothelioma - Pipeline Review, H2 2019

Table of Contents
Introduction
Malignant Mesothelioma - Overview
Malignant Mesothelioma - Therapeutics Development
Malignant Mesothelioma - Therapeutics Assessment
Malignant Mesothelioma - Companies Involved in Therapeutics Development
Malignant Mesothelioma - Drug Profiles
Malignant Mesothelioma - Dormant Projects
Malignant Mesothelioma - Discontinued Products
Malignant Mesothelioma - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Malignant Mesothelioma, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Universities/Institutes, H2 2019
Table 8: Products under Development by Companies, H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 15: Products under Development by Universities/Institutes, H2 2019
Table 16: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Target, H2 2019
Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 21: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 25: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 26: Number of Products by Stage and Route of Administration, H2 2019
Table 27: Number of Products by Stage and Molecule Type, H2 2019
Table 28: Malignant Mesothelioma - Pipeline by AbbVie Inc, H2 2019
Table 29: Malignant Mesothelioma - Pipeline by ADC Therapeutics SA, H2 2019
Table 30: Malignant Mesothelioma - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Table 31: Malignant Mesothelioma - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Table 32: Malignant Mesothelioma - Pipeline by Almac Discovery Ltd, H2 2019
Table 33: Malignant Mesothelioma - Pipeline by Amphera BV, H2 2019
Table 34: Malignant Mesothelioma - Pipeline by AnGes Inc, H2 2019
Table 35: Malignant Mesothelioma - Pipeline by Apollomics Inc, H2 2019
Table 36: Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences SL, H2 2019
Table 37: Malignant Mesothelioma - Pipeline by Argenx SE, H2 2019
Table 38: Malignant Mesothelioma - Pipeline by ArQule Inc, H2 2019
Table 39: Malignant Mesothelioma - Pipeline by Ascentage Pharma Group International, H2 2019
Table 40: Malignant Mesothelioma - Pipeline by AstraZeneca Plc, H2 2019
Table 41: Malignant Mesothelioma - Pipeline by Atara Biotherapeutics Inc, H2 2019
Table 42: Malignant Mesothelioma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Table 43: Malignant Mesothelioma - Pipeline by Bayer AG, H2 2019
Table 44: Malignant Mesothelioma - Pipeline by BerGenBio ASA, H2 2019
Table 45: Malignant Mesothelioma - Pipeline by Biocad, H2 2019
Table 46: Malignant Mesothelioma - Pipeline by Biogen Inc, H2 2019
Table 47: Malignant Mesothelioma - Pipeline by Bionomics Ltd, H2 2019
Table 48: Malignant Mesothelioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 49: Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H2 2019
Table 50: Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 51: Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H2 2019
Table 52: Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H2 2019
Table 53: Malignant Mesothelioma - Pipeline by Canget BioTekpharma LLC, H2 2019
Table 54: Malignant Mesothelioma - Pipeline by Checkpoint Therapeutics Inc, H2 2019
Table 55: Malignant Mesothelioma - Pipeline by Chiome Bioscience Inc, H2 2019
Table 56: Malignant Mesothelioma - Pipeline by Clovis Oncology Inc, H2 2019
Table 57: Malignant Mesothelioma - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
Table 58: Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Table 59: Malignant Mesothelioma - Pipeline by Delta-Fly Pharma Inc, H2 2019
Table 60: Malignant Mesothelioma - Pipeline by Eli Lilly and Co, H2 2019

List of Figures
Figure 1: Number of Products under Development for Malignant Mesothelioma, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
  • Global Cancer Immunomodulator Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
  • Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
  • Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125
    According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
  • Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112
    This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
  • Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
  • T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85
    CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
  • Global Kaposi Sarcoma Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107
    Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
  • Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs